These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 12905149)

  • 1. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin.
    Goldberg SV; Hanson D; Peloquin CA
    Clin Infect Dis; 2003 Aug; 37(4):607-8. PubMed ID: 12905149
    [No Abstract]   [Full Text] [Related]  

  • 2. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs for tuberculosis.
    Treat Guidel Med Lett; 2004 Dec; 2(28):83-8. PubMed ID: 15557876
    [No Abstract]   [Full Text] [Related]  

  • 5. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Mar; 49(9):185-9. PubMed ID: 11795500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin.
    Tattevin P; Revest M; Dupont M; Arvieux C; Michelet C
    Clin Infect Dis; 2003 Jan; 36(1):127-8. PubMed ID: 12491218
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
    Doi N
    Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of rifabutin, a rifamycin-class antibiotic, for the treatment of tuberculosis (A supplement to the 2008 revision of "Standards for tuberculosis care").
    ;
    Kekkaku; 2011 Jan; 86(1):43. PubMed ID: 21401006
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.
    Yamamoto T; Amitani R; Suzuki K; Tanaka E; Murayama T; Kuze F
    Antimicrob Agents Chemother; 1996 Feb; 40(2):426-8. PubMed ID: 8834891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
    Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
    Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with rifabutin replacing rifampin in the treatment of tuberculosis.
    Horne DJ; Spitters C; Narita M
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1485-9, i. PubMed ID: 22008761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
    Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease.
    Mitchison DA
    Soc Appl Bacteriol Symp Ser; 1996; 25():72S-80S. PubMed ID: 8972122
    [No Abstract]   [Full Text] [Related]  

  • 15. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.
    Klemens SP; Grossi MA; Cynamon MH
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2245-8. PubMed ID: 7840552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of tuberculosis with rifabutin in a renal transplant recipient.
    López-Montes A; Gallego E; López E; Pérez J; Lorenzo I; Llamas F; Serrano A; Andrés E; Illescas L; Gómez C
    Am J Kidney Dis; 2004 Oct; 44(4):e59-63. PubMed ID: 15384035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.
    Wasserman S; Antilus-Sainte R; Abdelgawad N; Odjourian NM; Cristaldo M; Dougher M; Kaya F; Zimmerman M; Denti P; Gengenbacher M
    Antimicrob Agents Chemother; 2024 Aug; 68(8):e0078324. PubMed ID: 39028192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
    Nettles RE; Mazo D; Alwood K; Gachuhi R; Maltas G; Wendel K; Cronin W; Hooper N; Bishai W; Sterling TR
    Clin Infect Dis; 2004 Mar; 38(5):731-6. PubMed ID: 14986259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation.
    Hickey MD; Quan DJ; Chin-Hong PV; Roberts JP
    Liver Transpl; 2013 Apr; 19(4):457-61. PubMed ID: 23526600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis.
    Barluenga J; Aznar F; García AB; Cabal MP; Palacios JJ; Menéndez MA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5717-22. PubMed ID: 16987658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.